Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?

被引：6

作者：

Saglio, Giuseppe ^{[1
]}

Fava, Carmen ^{[1
]}

Gale, Robert Peter ^{[2
]}

机构：

[1] Univ Turin, Mauriziano Hosp, Dept Clin & Biol Sci, Turin, Italy

[2] Imperial Coll London, Dept Med, Div Expt Med, Haematol Res Ctr, London, England

来源：

HAEMATOLOGICA | 2019年 / 104卷 / 05期

关键词：

MOLECULAR RESPONSE; IMATINIB TREATMENT; RANDOMIZED CML; SURVIVAL;

D O I：

10.3324/haematol.2018.214445

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：862 / 864

页数：3

共 23 条

[1] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[2] Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study [J].

Baccarani, Michele ;

Rosti, Gianantonio ;

Castagnetti, Fausto ;

Haznedaroglu, Ibrahim ;

Porkka, Kimmo ;

Abruzzese, Elisabetta ;

Alimena, Giuliana ;

Ehrencrona, Hans ;

Hjorth-Hansen, Henrik ;

Kairisto, Veli ;

Levato, Luciano ;

Martinelli, Giovanni ;

Nagler, Arnon ;

Nielsen, Johan Lanng ;

Ozbek, Ugur ;

Palandri, Francesca ;

Palmieri, Fausto ;

Pane, Fabrizio ;

Rege-Cambrin, Giovanna ;

Russo, Domenico ;

Specchia, Giorgina ;

Testoni, Nicoletta ;

Weiss-Bjerrum, Ole ;

Saglio, Giuseppe ;

Simonsson, Bengt .

BLOOD, 2009, 113 (19) :4497-4504

[3] Biomarker: Predictive or Prognostic? [J].

Ballman, Karla V. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) :3968-+

[4] Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease [J].

Branford, Susan ;

Wang, Paul ;

Yeung, David T. ;

Thomson, Daniel ;

Purins, Adrian ;

Wadham, Carol ;

Shahrin, Nur Hezrin ;

Marum, Justine E. ;

Nataren, Nathalie ;

Parker, Wendy T. ;

Geoghegan, Joel ;

Feng, Jinghua ;

Shanmuganathan, Naranie ;

Mueller, Martin C. ;

Dietz, Christian ;

Stangl, Doris ;

Donaldson, Zoe ;

Altamura, Haley ;

Georgievski, Jasmina ;

Braley, Jodi ;

Brown, Anna ;

Hahn, Christopher ;

Walker, Ieuan ;

Kim, Soo-Hyun ;

Choi, Soo-Young ;

Park, Sa-Hee ;

Kim, Dong-Wook ;

White, Deborah L. ;

Yong, Agnes S. M. ;

Ross, David M. ;

Scott, Hamish S. ;

Schreiber, Andreas W. ;

Hughes, Timothy P. .

BLOOD, 2018, 132 (09) :948-961

[5] The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era [J].

Breccia, Massimo ;

Alimena, Giuliana .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 79 (02) :135-143

[6] De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial [J].

Clark, Richard E. ;

Polydoros, Fotios ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Pocock, Christopher ;

Smith, Graeme ;

Byrne, Jenny L. ;

de lavallade, Hugues ;

O'Brien, Stephen G. ;

Coffey, Tony ;

Foroni, Letizia ;

Copland, Mhairi .

LANCET HAEMATOLOGY, 2017, 4 (07) :E310-E316

[7] Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study [J].

Cortes, Jorge E. ;

Baccarani, Michele ;

Guilhot, Francois ;

Druker, Brian J. ;

Branford, Susan ;

Kim, Dong-Wook ;

Pane, Fabrizio ;

Pasquini, Ricardo ;

Goldberg, Stuart L. ;

Kalaycio, Matt ;

Moiraghi, Beatriz ;

Rowe, Jacob M. ;

Tothova, Elena ;

De Souza, Carmino ;

Rudoltz, Marc ;

Yu, Richard ;

Krahnke, Tillmann ;

Kantarjian, Hagop M. ;

Radich, Jerald P. ;

Hughes, Timothy P. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :424-430

[8] High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses [J].

Cortes, Jorge E. ;

Kantarjian, Hagop M. ;

Goldberg, Stuart L. ;

Powell, Bayard L. ;

Giles, Francis J. ;

Wetzler, Meir ;

Akard, Luke ;

Burke, John M. ;

Kerr, Robert ;

Saleh, Mansoor ;

Salvado, August ;

McDougall, Karen ;

Albitar, Maher ;

Radich, Jerald .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4754-4759

[9] Landmark Analysis at the 25-Year Landmark Point [J].

Dafni, Urania .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (03) :363-U216

[10] Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy [J].

Eadie, Laura N. ;

Hughes, Timothy P. ;

White, Deborah L. .

LEUKEMIA, 2018, 32 (10) :2288-2291

← 1 2 3 →